Veloxis Pharma Announces Dosing by partner Xenikos in PIII Study of T-Guard
28 Jun 2022 //
PRNEWSWIRE
Xenikos Enrolls First Patient in Global Pivotal PIII Study Evaluating T-Guard
27 Jun 2022 //
GLOBENEWSWIRE
Xenikos Appoints Hassan Aly, MD, PhD as Chief Medical Officer
22 Sep 2021 //
GLOBENEWSWIRE